Rheumatoid Arthritis Clinical Trials in Philadelphia

Showing 561-580 of 3,347 trials

CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476

Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects will receive a single infusion of CART123 cells following ruxolitinib administration and lymphodepletion. Ruxolitinib dosing will begin at initiation of lymphodepleting chemotherapy (Day -6 ±1d) and continue for up to 14 days post CART123 administration.

Relapsed AMLRefractory AML

University of Pennsylvania12 participantsStarted Feb 2025

Philadelphia, Pennsylvania, United States

RECRUITINGNA< 1 mile

Assessment of CCM in HF With Higher Ejection Fraction

NCT05064709

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

Heart FailureHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection Fraction+2 more

Impulse Dynamics1,500 participantsStarted Feb 2022

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mesa, Arizona, United States +109 more locations

CART123 + Ruxolitinib in Relapsed/Refractory AML

Assessment of CCM in HF With Higher Ejection Fraction

Rheumatoid Arthritis Trials in Other Cities

Supportive Understanding and Patient-centered Partnership for Optimizing Renal Treatment

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study

Data Collection for the Validation of an Artificial Intelligence Software to Support Musculoskeletal Ultrasound Examination

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain

@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Other Conditions in Philadelphia